Comparative Pharmacology
Head-to-head clinical analysis: AEMCOLO versus MUPIROCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEMCOLO versus MUPIROCIN.
AEMCOLO vs MUPIROCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEMCOLO (crizotinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and mesenchymal-epithelial transition factor (MET). It inhibits ALK and ROS1 phosphorylation, blocking downstream signaling pathways involved in cell proliferation and survival.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
AEMCOLO (rifamycin) delayed-release tablets: 600 mg orally twice daily for 3 days. Take with or without food.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 18-22 hours, supporting once-daily dosing for maintained intraluminal concentrations.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Primarily fecal elimination as unchanged drug; approximately 90% of a dose is recovered in feces, with less than 1% excreted unchanged in urine. Biliary excretion accounts for the remainder.
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Category C
Category A/B
Antibiotic
Antibiotic